Replicated, replicable and relevant-target engagement and pharmacological experimentation in the 21st century.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Biochemical Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry, Computer Science

• Identifiers
  DOI 10.1016/j.bcp.2013.10.024PMID 24269285
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacology in 21st century biomedical research. Preface.

  2014cited by this paper
• Translational paradigms in pharmacology and drug discovery.

  2014cited by this paper
• Biomarkers in pharmacology and drug discovery.

  2014cited by this paper
• Pharmacokinetics.

  2014cited by this paper
• Defining and characterizing drug/compound function.

  2014cited by this paper
• The fall and rise of pharmacology--(re-)defining the discipline?

  2014cited by this paper
• Quantitative versus qualitative data: the numerical dimensions of drug action.

  2014cited by this paper
• Animal models of human disease: challenges in enabling translation.

  2014cited by this paper
• The use and misuse of statistical methodologies in pharmacology research.

  2014cited by this paper
• β-arrestins and G protein-coupled receptor trafficking.

  2014cited by this paper
• Who's afraid of peer review?

  2013cited by this paper
• Longitudinal imaging and analysis of neurons expressing polyglutamine-expanded proteins.

  2013cited by this paper
• Oral Treatment Targeting the Unfolded Protein Response Prevents Neurodegeneration and Clinical Disease in Prion-Infected Mice

  2013cited by this paper
• Target identification and mechanism of action in chemical biology and drug discovery.

  2013cited by this paper
• When is education a disservice?

  2013cited by this paper
• Shaking up science.

  2013cited by this paper
• Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond?

  2013cited by this paper
• Patents, profits, and the American people--the Bayh-Dole Act of 1980.

  2013cited by this paper
• The Separation of Politics and Science

  2013cited by this paper
• Driving students into science is a fool’s errand

  2013cited by this paper
• Scientists express growing reluctance to share study protocols

  2013cited by this paper
• Breaking a Vicious Cycle

  2013cited by this paper
• Building a New Biomedical Ecosystem: Pfizer's Centers for Therapeutic Innovation

  2013cited by this paper
• Power failure: why small sample size undermines the reliability of neuroscience

  2013cited by this paper
• Target deconvolution techniques in modern phenotypic profiling.

  2013cited by this paper
• The Organization of Innovation : The History of an Obsession (translated from "Die Organisation von Innovation", Merkur, No. 770, June 2013, by Shelley Frisch)

  2013cited by this paper
• Pharmacokinetics and the drug-target residence time concept.

  2013cited by this paper
• JAKs and STATs in immunity, immunodeficiency, and cancer.

  2013cited by this paper
• The organization of innovation--the history of an obsession.

  2013cited by this paper
• Threats to Validity in the Design and Conduct of Preclinical Efficacy Studies: A Systematic Review of Guidelines for In Vivo Animal Experiments

  2013cited by this paper
• Tumorsphere assay provides more accurate prediction of in vivo responses to chemotherapeutics

  2013cited by this paper
• Longitudinal measures of proteostasis in live neurons: Features that determine fate in models of neurodegenerative disease

  2013cited by this paper
• This I believe in genetics: discovery can be a nuisance, replication is science, implementation matters

  2013cited by this paper
• β-Arrestins and G protein-coupled receptor trafficking.

  2013cited by this paper
• Determining target engagement in living systems.

  2013cited by this paper
• Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay

  2013cited by this paper
• Reuse of public genome-wide gene expression data

  2012cited by this paper
• Drug development: Raise standards for preclinical cancer research

  2012cited by this paper
• Progressing preclinical drug candidates: strategies on preclinical safety studies and the quest for adequate exposure.

  2012cited by this paper
• Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors.

  2012cited by this paper
• Irreproducible experimental results: causes, (mis)interpretations, and consequences.

  2012cited by this paper
• Nitric oxide release: part II. Therapeutic applications.

  2012cited by this paper
• Phenotypic screening, take two

  2012cited by this paper
• p38 MAPK inhibitors, IKK2 inhibitors, and TNFα inhibitors in COPD.

  2012cited by this paper
• A call for transparent reporting to optimize the predictive value of preclinical research

  2012cited by this paper
• Translational semantics and infrastructure: another search for the emperor's new clothes?

  2012cited by this paper
• The functional size of GPCRs - monomers, dimers or tetramers?

  2012cited by this paper
• Translational Research and the Evolving Landscape for Biomedical Innovation

  2012cited by this paper
• Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.

  2012cited by this paper
• Diagnosing the decline in pharmaceutical R&D efficiency

  2012cited by this paper
• The cerebral cortex of Albert Einstein: a description and preliminary analysis of unpublished photographs

  2012cited by this paper
• The p38 MAPK Pathway in Rheumatoid Arthritis: A Sideways Look

  2012cited by this paper
• A Pharma Industry in Crisis

  2011cited by this paper
• Radioligand binding methods for membrane preparations and intact cells.

  2011cited by this paper
• Microglial p38α MAPK is critical for LPS-induced neuron degeneration, through a mechanism involving TNFα

  2011cited by this paper
• Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine.

  2011cited by this paper
• Productivity Shortfalls in Drug Discovery: Contributions from the Preclinical Sciences?

  2011cited by this paper
• The productivity crisis in pharmaceutical R&D

  2011cited by this paper
• Believe it or not: how much can we rely on published data on potential drug targets?

  2011cited by this paper
• Role of p53 in Neurodegenerative Diseases

  2011cited by this paper
• What makes a good drug target?

  2011cited by this paper
• Reforming Science: Methodological and Cultural Reforms

  2011cited by this paper
• Reductionistic and Holistic Science

  2011cited by this paper
• Education: The PhD factory

  2011cited by this paper
• The problem of pseudoreplication in neuroscientific studies: is it affecting your analysis?

  2010cited by this paper
• Mechanisms and functions of p38 MAPK signalling.

  2010cited by this paper
• Reporting : The ARRIVE Guidelines for Reporting Animal Research

  2010cited by this paper
• Molecular mechanisms in signal transduction at the membrane

  2010cited by this paper
• Serotonin derivatives as a new class of non-ATP-competitive receptor tyrosine kinase inhibitors.

  2010cited by this paper
• “Where, O Death, Is Thy Sting?” A Brief Review of Apoptosis Biology

  2010cited by this paper
• Guidelines for the welfare and use of animals in cancer research

  2010cited by this paper
• A new research and development policy framework for the biomedical research enterprise.

  2010cited by this paper
• How Many Scientists Fabricate and Falsify Research? A Systematic Review and Meta-Analysis of Survey Data

  2009cited by this paper
• Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets.

  2009cited by this paper
• Stroke research at a road block: the streets from adversity should be paved with meta‐analysis and good laboratory practice

  2009cited by this paper
• Assessing the translatability of drug projects: what needs to be scored to predict success?

  2009cited by this paper
• The influence of lead discovery strategies on the properties of drug candidates

  2009cited by this paper
• Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors

  2009cited by this paper
• Programmed Cell Death Pathways and Current Antitumor Targets

  2009cited by this paper
• Novel trends in high-throughput screening.

  2009cited by this paper
• Awakening guardian angels: drugging the p53 pathway

  2009cited by this paper
• Effects of NXY‐059 in experimental stroke: an individual animal meta‐analysis

  2009cited by this paper
• Residence time of receptor-ligand complexes and its effect on biological function.

  2008cited by this paper
• Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma

  2008cited by this paper
• The BCL-2 protein family: opposing activities that mediate cell death

  2008cited by this paper
• Laboratory Notebooks and Data Storage

  2008cited by this paper
• A quantitative analysis of kinase inhibitor selectivity

  2008cited by this paper
• Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals

  2007cited by this paper
• Mechanistic pathways and biological roles for receptor-independent activators of G-protein signaling.

  2007cited by this paper
• Integrating cell-signalling pathways with NF-kappaB and IKK function.

  2007cited by this paper
• Integrating cell-signalling pathways with NF-κB and IKK function

  2007cited by this paper
• Recent developments in nitric oxide donor drugs

  2007cited by this paper
• Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting.

  2007cited by this paper
• The selectivity of protein kinase inhibitors: a further update.

  2007cited by this paper
• A radical role for p38 MAPK in tumor initiation.

  2007cited by this paper
• Rising Above "The Gathering Storm"

  2007cited by this paper
• Drug discovery in jeopardy.

  2006cited by this paper
• The moral corporation - Merck experiences

  2006cited by this paper
• Phosphodiesterase inhibitors

  2006cited by this paper
• Science Business: The Promise, the Reality, and the Future of Biotech

  2006cited by this paper

• Exploring medicinal plants for antiparamphistomiasis: A scoping review of pharmacological insights and methodologies.

  2025cites this paper
• Biased signaling in drug discovery and precision medicine.

  2025cites this paper
• In Silico Modeling Demonstrates that User Variability During Tumor Measurement Can Affect In Vivo Therapeutic Efficacy Outcomes

  2022cites this paper
• Ethnopharmacology and the Development of Psychoactive Drug: A Critical Overview

  2021cites this paper
• Cellular target engagement: a new paradigm in drug discovery.

  2018cites this paper
• Publication trends of study protocols in rehabilitation.

  2018cites this paper
• Experimental Planning and Execution

  2018cites this paper
• Chapter 1 – Reproducibility in Biomedical Research

  2018cites this paper
• Detecting drug-target binding in cells using fluorescence-activated cell sorting coupled with mass spectrometry analysis

  2017cites this paper
• Doctoral and professional programs

  2017cites this paper
• Drug discovery: Standing on the shoulders of giants

  2017cites this paper
• Modulation of learning and memory by natural polyamines.

  2016cites this paper
• Receptor-ligand interactions: Advanced biomedical applications.

  2016cites this paper
• The Cellular Thermal Shift Assay: A Novel Biophysical Assay for In Situ Drug Target Engagement and Mechanistic Biomarker Studies.

  2016cites this paper
• Reproducibility in Science: Improving the Standard for Basic and Preclinical Research

  2015cites this paper
• Biased agonism at kappa opioid receptors: Implication in pain and mood disorders.

  2015cites this paper
• Do We Need a Science of Science

  2015cites this paper
• Experimental design and analysis and their reporting: new guidance for publication in BJP

  2015cites this paper
• Target engagement in lead generation.

  2015cites this paper
• Guidelines for manuscript submission in the peer-reviewed pharmacological literature.

  2015cites this paper
• Quantitative versus qualitative data: the numerical dimensions of drug action.

  2014cites this paper
• The future of drug discovery: enabling technologies for enhancing lead characterization and profiling therapeutic potential

  2014cites this paper
• Reproducibility in Science Improving the Standard for Basic and Preclinical Research

  2014cites this paper
• Translational paradigms in pharmacology and drug discovery.

  2014cites this paper
• Defining and characterizing drug/compound function.

  2014cites this paper